Trial reportJournal of acquired immune deficiency syndromes (1999)2026
Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings.
Trial report in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundWe investigated whether serum levels of biomarkers of inflammation, immune activation, and angiogenesis, which have been implicated in the pathogenesis of Kaposi sarcoma (KS), were associated with tumor burden and treatment response of advanced AIDS-KS.
methodsParticipants with advanced, previously untreated AIDS-KS enrolled in AMC066/ACTG A5263, a prospective, randomized trial conducted in sub-Saharan Africa and South America, were randomly assigned to either paclitaxel (PTX)+ART or bleomycin/vincristine (BV)+ART. Biomarkers of inflammation (C-reactive protein, IL-6, IL-8, IL-10, G-CSF, sTNF-RII), immune activation (sCD25/sIL-2Rα, CXCL10/IP-10, CCL2/MCP1), and angiogenesis (MMP-9, soluble endoglin, vascular endothelial growth factor, MMP-2, and hepatocyte growth factor) were measured by Luminex to determine whether pre- or post-treatment levels were associated with KS response and tumor burden. Wilcoxon rank-sum tests were used to compare biomarkers levels between groups.
resultsOne hundred thirty-one participants met the analysis inclusion criteria (70 PTX, 61 BV; 82 nonprogressors, 49 progressors). Higher baseline KS tumor burden was associated with higher pretreatment inflammatory and immune activation biomarker levels, and lower levels of markers with angiogenesis-inhibitory activity. Associations of baseline biomarker levels with subsequent KS response were not observed; however, progressors showed higher levels of several markers of inflammation and immune activation (IL-6, IL-10, sTNF-RII, and IP-10) than nonprogressors at weeks 3 and 12.
conclusionsPretreatment biomarker levels were associated with greater KS tumor burden but not with KS response to chemotherapy + ART in people with advanced AIDS-KS. Differential levels of several serum biomarkers were noted on treatment in progressors and nonprogressors, suggesting that increased tumor burden was associated with higher levels of inflammation and immune activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.